Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

Cheng et al. (Fri,) studied this question.

www.synapsesocial.com/papers/68e58925b6db643587525346 — DOI: https://doi.org/10.1056/nejmoa2404873

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial· 2024 · 22 citations
2. Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody· 2015 · 407 citations
3. SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)· 2023 · 30 citations
4. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial· 2019 · 2,156 citations
5. Systemic therapy for limited stage small cell lung carcinoma· 2020 · 24 citations